Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 2;9(6):e002568. doi: 10.1136/jitc-2021-002568

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Overall survival in patients with HNSCC who were reported as undergoing surgery in the HPV-positive (n=18) and HPV-negative (n=20) cohorts. Median follow-up for these cohorts was 34.3 months (range, 19.1 to 52.3) and 37.1 months (range, 2.7 to 53.9), respectively. In the HPV-positive cohort, there were no on-study deaths. In the HPV-negative cohort, there were nine on-study deaths from disease progression (n=6) or adverse events unrelated to neoadjuvant nivolumab or protocol surgery (n=3). HPV, human papillomavirus; NE, not estimable; NR, not reached; OS, overall survival. ^aAfter database lock, one patient in the HPV-negative cohort was found to have received a planned post-nivolumab biopsy instead of complete surgical resection; OS for this patient was 49.8 months.